ERIS — Eris Lifesciences Balance Sheet
0.000.00%
- IN₹214.16bn
- IN₹241.33bn
- IN₹28.94bn
- 90
- 10
- 67
- 59
Annual balance sheet for Eris Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | R2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 873 | 1,504 | 860 | 13,388 | 2,054 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,191 | 2,713 | 4,593 | 5,712 | 5,825 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4,670 | 6,273 | 7,647 | 23,020 | 12,230 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 779 | 1,919 | 3,774 | 5,583 | 7,288 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 18,348 | 22,721 | 36,673 | 70,405 | 70,332 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,669 | 1,996 | 4,432 | 25,321 | 13,814 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,584 | 3,638 | 14,713 | 44,543 | 41,788 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 15,764 | 19,083 | 21,960 | 25,862 | 28,544 |
| Total Liabilities & Shareholders' Equity | 18,348 | 22,721 | 36,673 | 70,405 | 70,332 |
| Total Common Shares Outstanding |